WO2008126899A1 - 5員環へテロ環誘導体及びその医薬用途 - Google Patents

5員環へテロ環誘導体及びその医薬用途 Download PDF

Info

Publication number
WO2008126899A1
WO2008126899A1 PCT/JP2008/057093 JP2008057093W WO2008126899A1 WO 2008126899 A1 WO2008126899 A1 WO 2008126899A1 JP 2008057093 W JP2008057093 W JP 2008057093W WO 2008126899 A1 WO2008126899 A1 WO 2008126899A1
Authority
WO
WIPO (PCT)
Prior art keywords
independently represent
membered heterocyclic
heterocyclic derivative
haloalkyl
prophylactic
Prior art date
Application number
PCT/JP2008/057093
Other languages
English (en)
French (fr)
Inventor
Kazuo Shimizu
Yasushi Takigawa
Hideki Fujikura
Masato Iizuka
Masahiro Hiratochi
Norihiko Kikuchi
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009010491A priority Critical patent/MX2009010491A/es
Priority to CA2682393A priority patent/CA2682393C/en
Priority to KR1020097021439A priority patent/KR101502959B1/ko
Priority to CN200880018819.3A priority patent/CN101679244B/zh
Priority to RU2009141613/04A priority patent/RU2515968C2/ru
Priority to AU2008239018A priority patent/AU2008239018B2/en
Application filed by Kissei Pharmaceutical Co., Ltd. filed Critical Kissei Pharmaceutical Co., Ltd.
Priority to US12/595,437 priority patent/US8227500B2/en
Priority to BRPI0810523-5A2A priority patent/BRPI0810523A2/pt
Priority to EP08740194A priority patent/EP2133331A4/en
Priority to JP2009509372A priority patent/JP5378988B2/ja
Publication of WO2008126899A1 publication Critical patent/WO2008126899A1/ja
Priority to US13/494,380 priority patent/US9023882B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4021-aryl substituted, e.g. piretanide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

本発明は、血漿尿酸値異常に起因する疾患等の予防又は治療薬として有用な化合物を提供する。すなわち、本発明は、キサンチンオキシダーゼ阻害活性を有し、血漿尿酸値異常に起因する疾患の予防又は治療薬として有用な、下記一般式(I)で表される5員環へテロ環誘導体、そのプロドラッグ、その塩等に関する。式(I)中、Tはニトロ、シアノ等;環Jはアリール又はヘテロアリール;Qはカルボキシ、5-テトラゾリル等;YはH、OH、NH2、ハロゲン、ハロアルキル等;X1、X2は独立してCR2又はN;R2はH、アルキル等;R1はハロゲン、シアノ、ハロアルキル、A-D-E-G-L-M、-N(-D-L-M)2等(式中、Aは単結合、O、S等;D、G及びMは独立して置換可アルキレン、シクロアルキレン、ヘテロシクロアルキレン、アリーレン、ヘテロアリーレン等;E及びLは独立して単結合、O、S、COO、SO2等;である。
PCT/JP2008/057093 2007-04-11 2008-04-10 5員環へテロ環誘導体及びその医薬用途 WO2008126899A1 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2682393A CA2682393C (en) 2007-04-11 2008-04-10 5-membered heterocyclic derivative and use thereof for medical purposes
KR1020097021439A KR101502959B1 (ko) 2007-04-11 2008-04-10 5원환 헤테로환 유도체 및 그 의약 용도
CN200880018819.3A CN101679244B (zh) 2007-04-11 2008-04-10 5元杂环衍生物及其医药用途
RU2009141613/04A RU2515968C2 (ru) 2007-04-11 2008-04-10 5-членное гетероциклическое соединение и его применение для лекарственных целей
AU2008239018A AU2008239018B2 (en) 2007-04-11 2008-04-10 5-membered heterocyclic derivative and use thereof for medical purposes
MX2009010491A MX2009010491A (es) 2007-04-11 2008-04-10 Derivado heterociclico de 5 miembros y su uso para propositos medicos.
US12/595,437 US8227500B2 (en) 2007-04-11 2008-04-10 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
BRPI0810523-5A2A BRPI0810523A2 (pt) 2007-04-11 2008-04-10 Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
EP08740194A EP2133331A4 (en) 2007-04-11 2008-04-10 FIVE-GLASS HETEROCYCLIC DERIVATIVE AND ITS USE IN MEDICAL PURPOSES
JP2009509372A JP5378988B2 (ja) 2007-04-11 2008-04-10 5員環へテロ環誘導体及びその医薬用途
US13/494,380 US9023882B2 (en) 2007-04-11 2012-06-12 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-104094 2007-04-11
JP2007104094 2007-04-11

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/595,437 A-371-Of-International US8227500B2 (en) 2007-04-11 2008-04-10 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
US13/494,380 Division US9023882B2 (en) 2007-04-11 2012-06-12 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
US13/494,380 Continuation US9023882B2 (en) 2007-04-11 2012-06-12 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
WO2008126899A1 true WO2008126899A1 (ja) 2008-10-23

Family

ID=39863994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057093 WO2008126899A1 (ja) 2007-04-11 2008-04-10 5員環へテロ環誘導体及びその医薬用途

Country Status (11)

Country Link
US (2) US8227500B2 (ja)
EP (1) EP2133331A4 (ja)
JP (1) JP5378988B2 (ja)
KR (1) KR101502959B1 (ja)
CN (1) CN101679244B (ja)
AU (1) AU2008239018B2 (ja)
BR (1) BRPI0810523A2 (ja)
CA (1) CA2682393C (ja)
MX (1) MX2009010491A (ja)
RU (1) RU2515968C2 (ja)
WO (1) WO2008126899A1 (ja)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044410A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ビアリールイソニコチン酸誘導体及びその医薬用途
WO2010044403A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 5員環ヘテロアリール誘導体及びその医薬用途
WO2011043568A2 (en) 2009-10-07 2011-04-14 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
US8748452B2 (en) 2009-03-31 2014-06-10 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes
WO2014119681A1 (ja) * 2013-01-31 2014-08-07 帝人ファーマ株式会社 アゾールベンゼン誘導体
WO2014121695A1 (zh) * 2013-02-08 2014-08-14 镇江新元素医药科技有限公司 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物
WO2015174417A1 (ja) * 2014-05-13 2015-11-19 帝人ファーマ株式会社 ピラジン誘導体
WO2016017826A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬
WO2016017708A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 アゾールベンゼン誘導体およびその結晶
WO2016017696A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 アゾールベンゼン誘導体の結晶
JP2016534056A (ja) * 2013-10-21 2016-11-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Btk阻害剤としてのヘテロアリール化合物及びその使用
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
WO2017063966A1 (en) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
US9802899B2 (en) 2012-10-02 2017-10-31 Bayer Cropscience Ag Heterocyclic compounds as pesticides
JP2020533386A (ja) * 2017-09-12 2020-11-19 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ イソプレニルシステインカルボキシルメチルトランスフェラーゼ阻害剤として有用な化合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110672A1 (es) * 2008-08-14 2011-09-25 Bayer Cropscience Ag 4-fenil-1-h-pirazoles insecticidas
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
EP2917203B1 (en) * 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Method for identifying myc inhibitors
US9604961B2 (en) 2012-12-06 2017-03-28 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP2017165653A (ja) * 2014-07-30 2017-09-21 帝人ファーマ株式会社 アゾールカルボン酸誘導体
WO2016202758A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
CN106146419A (zh) * 2016-08-01 2016-11-23 沈阳药科大学 黄嘌呤氧化酶抑制剂
ES2639863B1 (es) * 2017-03-10 2018-09-20 Universidad De Granada Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
MX2022004713A (es) * 2019-10-30 2022-05-11 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.
TW202313568A (zh) * 2021-05-21 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 Btk抑制劑中間體的製備方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511243A (ja) * 1993-05-17 1996-11-26 藤沢薬品工業株式会社 細胞におけるNa▲上+▼/H▲上+▼交換の阻害剤としてのグアニジン誘導体
WO1997046530A1 (en) * 1996-06-06 1997-12-11 E.I. Du Pont De Nemours And Company Herbicidal pyridinyl and pyrazolylphenyl ketones
JP2000001431A (ja) 1998-06-15 2000-01-07 Kotobuki Seiyaku Kk 尿酸排泄剤
JP3220987B2 (ja) * 1996-10-25 2001-10-22 ウェルファイド株式会社 1−フェニルピラゾール化合物およびその医薬用途
US6511974B1 (en) * 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
WO2003042181A1 (fr) * 2001-11-16 2003-05-22 Yamanouchi Pharmaceutical Co., Ltd. Derives de 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine, ou sels desdits derives
JP2006012642A (ja) 2004-06-25 2006-01-12 Matsushita Electric Works Ltd 放電灯点灯装置
JP2006021462A (ja) 2004-07-09 2006-01-26 Toray Ind Inc 易接着ポリエステルフィルム、それを用いた難燃性ポリエステルフィルムおよび銅張り積層板
WO2007043401A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187185A (en) * 1988-12-09 1993-02-16 Rhone-Poulenc Ag Company Pesticidal 1-arylpyrroles
JPS62153273A (ja) * 1985-12-26 1987-07-08 Tokuyama Soda Co Ltd ピラゾ−ル化合物
DE3919435A1 (de) * 1989-06-14 1990-12-20 Basf Ag Salicylaldehyd- und salicylsaeurederivate sowie deren schwefelanaloge, verfahren zu ihrer herstellung als herbizide und bioregulatoren
US5215994A (en) * 1990-09-25 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic derivatives
ES2193609T3 (es) * 1993-11-30 2003-11-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas y su uso como inhibidores de la ciclooxigenasa ii.
US5859215A (en) 1995-10-25 1999-01-12 Wallac Oy Biospecific binding reactants labelled with luminescent lanthanide chelates and their use
EP1076053B1 (en) * 1998-04-27 2006-11-29 Kumiai Chemical Industry Co., Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
EP1076656A2 (en) * 1998-04-28 2001-02-21 Novartis AG N-heteroaryl-substituted pyridine derivatives and their use as herbicides
US6180295B1 (en) * 1998-09-11 2001-01-30 Eastman Kodak Company Liquid crystalline filter dyes for imaging elements
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
WO2003037335A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
PT1452528E (pt) * 2001-11-16 2008-10-14 Nippon Chemiphar Co Inibidores de xantina-oxidase
WO2003073999A2 (en) * 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
BRPI0416983A (pt) * 2003-12-12 2007-02-21 Syngenta Participations Ag herbicidas
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511243A (ja) * 1993-05-17 1996-11-26 藤沢薬品工業株式会社 細胞におけるNa▲上+▼/H▲上+▼交換の阻害剤としてのグアニジン誘導体
WO1997046530A1 (en) * 1996-06-06 1997-12-11 E.I. Du Pont De Nemours And Company Herbicidal pyridinyl and pyrazolylphenyl ketones
JP3220987B2 (ja) * 1996-10-25 2001-10-22 ウェルファイド株式会社 1−フェニルピラゾール化合物およびその医薬用途
US6511974B1 (en) * 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
JP2000001431A (ja) 1998-06-15 2000-01-07 Kotobuki Seiyaku Kk 尿酸排泄剤
WO2003042181A1 (fr) * 2001-11-16 2003-05-22 Yamanouchi Pharmaceutical Co., Ltd. Derives de 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine, ou sels desdits derives
JP2006012642A (ja) 2004-06-25 2006-01-12 Matsushita Electric Works Ltd 放電灯点灯装置
JP2006021462A (ja) 2004-07-09 2006-01-26 Toray Ind Inc 易接着ポリエステルフィルム、それを用いた難燃性ポリエステルフィルムおよび銅張り積層板
WO2007043401A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
WO2007043400A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素芳香族複素環化合物およびそれを含有する医薬組成物

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"New drug Drug delivery system", vol. 42, 31 January 2000, CMC CO., LTD., pages: 67 - 173
"Renal Fluid Electrolyte Physiol.", AM. J. PHYSIOL., vol. 35, 1994, pages F797 - F805
ATSUO TANIGUCHI, MODERN PHYSICIAN, vol. 24, no. 8, 2004, pages 1309 - 1312
ATSUSHI ENOMOTO, NATURE, vol. 417, 2002, pages 447 - 452
BALSAMO A. ET AL.: "Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, 2003, pages 157 - 168, XP004413075 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 16, 2002, pages 2105 - 2108
COBB J. ET AL.: "Synthesis and Reactions of 1-Aryl-2-nitropyrroles. Structural and Conformational Study of Ethyl N-[2'-[1'-(2-nitropyrrolyl]phenyl-N-toluene-4-sulfonamide glycinate", TETRAHEDRON, vol. 52, no. 12, 1996, pages 4485 - 4494, XP004104245 *
FRANCOISE ROCH-RAMEL, J. PHARMACOL. EXP. THER., vol. 280, 1997, pages 839 - 845
FRANCOISE ROCH-RAMEL: "Renal Fluid Electrolyte Physiol.", AM. J. PHYSIOL., vol. 266, 1994, pages F797 - F805
HIDEKI HORIUCHI, LIFE SCIENCE, vol. 66, no. 21, 2000, pages 2051 - 2070
HIROAKI KIMURA: "Nihon rinsyo", vol. 61, 2003, pages: 119 - 123
HISASHI YAMANAKA: "Konyosankessyo to Tsufu", vol. 2, 1994, MEDICAL REVIEW CO., pages: 103 - 111
KAZUHIDE OGINO: "Nihon Rinsho (Japan Clinical)", vol. 61, 2003, pages: 197 - 201
M. D. FEHER, RHEUMATOLOGY, vol. 42, 2003, pages 321 - 325
NIHON, TSUHU KAKUSAN TAISYA GAKKAI, 2002, pages 32 - 33
S TAKAHASHI, ANN. RHEUM. DIS., vol. 62, 2003, pages 572 - 575
See also references of EP2133331A4 *
ZHIFENG YU, J. PHARMACOL. EXP. THER., vol. 316, 2006, pages 169 - 175

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2010044403A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 5員環ヘテロアリール誘導体及びその医薬用途
WO2010044410A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ビアリールイソニコチン酸誘導体及びその医薬用途
US8748452B2 (en) 2009-03-31 2014-06-10 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes
WO2011043568A2 (en) 2009-10-07 2011-04-14 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
US10961201B2 (en) 2012-10-02 2021-03-30 Bayer Cropscience Ag Heterocyclic compounds as pesticides
US9802899B2 (en) 2012-10-02 2017-10-31 Bayer Cropscience Ag Heterocyclic compounds as pesticides
US10435374B2 (en) 2012-10-02 2019-10-08 Bayer Cropscience Ag Heterocyclic compounds as pesticides
US10689348B2 (en) 2012-10-02 2020-06-23 Bayer Cropscience Ag Heterocyclic compounds as pesticides
US11548854B2 (en) 2012-10-02 2023-01-10 Bayer Cropscience Ag Heterocyclic compounds as pesticides
US11332448B2 (en) 2012-10-02 2022-05-17 Bayer Cropscience Ag Heterocyclic compounds as pesticides
WO2014119681A1 (ja) * 2013-01-31 2014-08-07 帝人ファーマ株式会社 アゾールベンゼン誘導体
US9388174B2 (en) 2013-01-31 2016-07-12 Teijin Pharma Limited Azole benzene derivative
JP5734532B2 (ja) * 2013-01-31 2015-06-17 帝人ファーマ株式会社 アゾールベンゼン誘導体
RU2641891C2 (ru) * 2013-01-31 2018-01-23 Тейдзин Фарма Лимитед Азоловые производные бензола
WO2014121695A1 (zh) * 2013-02-08 2014-08-14 镇江新元素医药科技有限公司 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物
JP2016534056A (ja) * 2013-10-21 2016-11-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Btk阻害剤としてのヘテロアリール化合物及びその使用
WO2015174417A1 (ja) * 2014-05-13 2015-11-19 帝人ファーマ株式会社 ピラジン誘導体
JPWO2015174417A1 (ja) * 2014-05-13 2017-04-20 帝人ファーマ株式会社 ピラジン誘導体
US9856237B2 (en) 2014-05-13 2018-01-02 Teijin Pharma Limited Pyrazine derivatives
JPWO2016017696A1 (ja) * 2014-07-30 2017-04-27 帝人ファーマ株式会社 アゾールベンゼン誘導体の結晶
WO2016017708A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 アゾールベンゼン誘導体およびその結晶
JPWO2016017826A1 (ja) * 2014-07-30 2017-04-27 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬
JPWO2016017708A1 (ja) * 2014-07-30 2017-04-27 帝人ファーマ株式会社 アゾールベンゼン誘導体およびその結晶
RU2675854C2 (ru) * 2014-07-30 2018-12-25 Тейдзин Фарма Лимитед Кристаллическая форма азолбензольного производного
US10179780B2 (en) 2014-07-30 2019-01-15 Teijin Pharma Limited Azole benzene derivative and crystalline form thereof
US10301300B2 (en) 2014-07-30 2019-05-28 Teijin Limited Xanthine oxidase inhibitor
AU2015297489B2 (en) * 2014-07-30 2019-09-19 Teijin Limited Crystal of azole benzene derivative
RU2701515C2 (ru) * 2014-07-30 2019-09-27 Тейдзин Фарма Лимитед Производное азолобензола и его кристаллическая форма
WO2016017826A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬
US9815826B2 (en) 2014-07-30 2017-11-14 Teijin Pharma Limited Crystal of azole benzene derivative
WO2016017696A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 アゾールベンゼン誘導体の結晶
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
WO2017063966A1 (en) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
JP2020533386A (ja) * 2017-09-12 2020-11-19 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ イソプレニルシステインカルボキシルメチルトランスフェラーゼ阻害剤として有用な化合物
JP7334979B2 (ja) 2017-09-12 2023-08-29 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ イソプレニルシステインカルボキシルメチルトランスフェラーゼ阻害剤として有用な化合物
US11834430B2 (en) 2017-09-12 2023-12-05 Agency For Science, Technology And Research Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase

Also Published As

Publication number Publication date
KR101502959B1 (ko) 2015-03-16
AU2008239018B2 (en) 2013-09-05
CA2682393A1 (en) 2008-10-23
CN101679244B (zh) 2014-01-01
MX2009010491A (es) 2009-11-09
AU2008239018A1 (en) 2008-10-23
JP5378988B2 (ja) 2013-12-25
RU2515968C2 (ru) 2014-05-20
US20120289506A1 (en) 2012-11-15
US20100227864A1 (en) 2010-09-09
KR20090128489A (ko) 2009-12-15
EP2133331A4 (en) 2011-06-22
CN101679244A (zh) 2010-03-24
EP2133331A1 (en) 2009-12-16
US8227500B2 (en) 2012-07-24
JPWO2008126899A1 (ja) 2010-07-22
US9023882B2 (en) 2015-05-05
CA2682393C (en) 2015-03-17
BRPI0810523A2 (pt) 2014-10-21
RU2009141613A (ru) 2011-05-20

Similar Documents

Publication Publication Date Title
WO2008126899A1 (ja) 5員環へテロ環誘導体及びその医薬用途
WO2008126898A1 (ja) (アザ)インドール誘導体及びその医薬用途
PT2415771E (pt) Derivado de indolizina e sua utilização para fins médicos
WO2011004162A3 (en) 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2007026920A3 (en) Amide derivatives as rock inhibitors
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
WO2006112549A8 (ja) 縮合複素環化合物
WO2008108380A3 (en) Pyrrole compounds
EP1889842A4 (en) HETEROCYCLIC CONNECTION
WO2008093674A1 (ja) キナーゼ阻害活性を有する新規チアジアゾール誘導体
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
WO2009038064A1 (ja) I型11βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
WO2009050352A3 (fr) Derives d'imidazolones, procede de preparation et applications biologiques
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
WO2010010288A3 (fr) Derives de carbamates d' alkylthiazoles, leur preparation et leur utilisation comme inhbiteurs de l'enzyme faah
WO2007025897A3 (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
WO2006127379A3 (en) Par2-modulating compounds and their use
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
WO2006051314A8 (en) Guanidine derivatives as inhibitors of ddah

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880018819.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740194

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009509372

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2682393

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 6236/DELNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/010491

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2008740194

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008239018

Country of ref document: AU

Ref document number: 2008740194

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12595437

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20097021439

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008239018

Country of ref document: AU

Date of ref document: 20080410

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009141613

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0810523

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091009